Search results
Results from the WOW.Com Content Network
Pulmonary rehabilitation is generally specific to the individual patient, with the objective of meeting the needs of the patient. It is a broad program and may benefit patients with lung diseases such as chronic obstructive pulmonary disease (COPD), sarcoidosis, idiopathic pulmonary fibrosis (IPF) and cystic fibrosis, among others.
Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by chronic respiratory symptoms and airflow limitation. [8] GOLD 2024 defined COPD as a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea or shortness of breath, cough, sputum production or exacerbations) due to abnormalities of the airways (bronchitis ...
The definition of a COPD exacerbation is commonly described as "lost in translation", [9] meaning that there is no universally accepted standard with regard to defining an acute exacerbation of COPD. Many organizations consider it a priority to create such a standard, as it would be a major step forward in the diagnosis and quality of treatment ...
COPD: chronic obstructive pulmonary disease: CO 2: carbon dioxide: COVID: coronavirus disease: COX-1: cyclooxygenase 1: COX-2: cyclooxygenase 2: COX-3: cyclooxygenase 3: CP: cerebral palsy chest pain constrictive pericarditis: CPAP: continuous positive airway pressure: CPC: clinical–pathological conference CPCR: cardiopulmonary-cerebral ...
The image above shows the difference between a normal, healthy lung (left) and a COPD patient's lung (right). Chronic obstructive pulmonary disease (COPD), is a progressive lung disease. The term COPD includes two main conditions: (1) emphysema and (2) chronic bronchitis.
This product was approved by the FDA in May 2013 as once-daily inhaled therapy for the treatment of chronic obstructive pulmonary disease (COPD) with umeclidinium bromide: Anoro Ellipta. Umeclidinium bromide is a long-acting muscarinic antagonist. [14]
CURB-65, also known as the CURB criteria, is a clinical prediction rule that has been validated for predicting mortality in community-acquired pneumonia [1] and infection of any site. [2]
Doxofylline (also known as doxophylline) is a phosphodiesterase inhibiting bronchodilator used in the treatment of chronic respiratory diseases such as asthma [1] and COPD. [2] Like theophylline, it is a xanthine derivative. [3] [4]